Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyCellularComponentnuclear body

MAML1 ILRUN NCOR2 IFI16 USP28 ZNF174 MEF2C ADD1

9.17e-06903268GO:0016604
DomainUBA-like

ILRUN USP28

3.84e-0364272IPR009060
Domain-

NRXN3 LMAN1

8.27e-03952722.60.120.200
Pubmed

PRISMA and BioID disclose a motifs-based interactome of the intrinsically disordered transcription factor C/EBPα.

MAML1 LARP1 EPRS1 NCOR2 LMAN1 DDX55 AP2B1 IFI16 MBD2 ZNF174

5.10e-091103271034189442
Pubmed

Overlapping Activities of Two Neuronal Splicing Factors Switch the GABA Effect from Excitatory to Inhibitory by Regulating REST.

CPEB3 EPRS1 NRXN3 MEF2C ADD1

4.72e-0812827530995482
Pubmed

Prediction of the coding sequences of mouse homologues of KIAA gene: III. the complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.

MAML1 LARP1 NRXN3 DDX55 USP28 WNK2

2.72e-0652927614621295
Pubmed

The Notch coactivator, MAML1, functions as a novel coactivator for MEF2C-mediated transcription and is required for normal myogenesis.

MAML1 MEF2C

3.48e-06427216510869
Pubmed

Transcriptional mechanisms by the coregulator MAML1.

MAML1 MEF2C

5.80e-06527219751190
Pubmed

Exploring Regulatory Mechanisms of Atrial Myocyte Hypertrophy of Mitral Regurgitation through Gene Expression Profiling Analysis: Role of NFAT in Cardiac Hypertrophy.

MEF2C PLCE1

5.80e-06527227907007
Pubmed

Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.

NCOR2 PARD3 AP2B1 USP28 FAM81A WNK2 ADD1

6.68e-0696327728671696
Pubmed

Defining the membrane proteome of NK cells.

LARP1 EPRS1 NCOR2 LMAN1 DDX55 AP2B1 IFI16

2.33e-05116827719946888
Pubmed

Large-scale characterization of HeLa cell nuclear phosphoproteins.

LARP1 EPRS1 NCOR2 PARD3 IFI16 ADD1

2.37e-0577427615302935
Pubmed

Proteomic analyses reveal distinct chromatin-associated and soluble transcription factor complexes.

MAML1 LARP1 NCOR2 MBD2 USP28 MEF2C

4.18e-0585727625609649
Pubmed

HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation.

LARP1 EPRS1 DDX55 PARD3 AP2B1 MBD2 ADD1

6.46e-05137127736244648
Pubmed

Characterization of human colon cancer antigens recognized by autologous antibodies.

MBD2 WNK2

6.92e-05162729610721
Pubmed

MEF2C regulates cortical inhibitory and excitatory synapses and behaviors relevant to neurodevelopmental disorders.

NRXN3 MEF2C

7.84e-051727227779093
Pubmed

In-Depth In Vivo Crosslinking in Minutes by a Compact, Membrane-Permeable, and Alkynyl-Enrichable Crosslinker.

LARP1 EPRS1 NRXN3 DDX55 AP2B1 ZNF174 PPP4R4

8.88e-05144227735575683
Pubmed

Interactions of the Antiviral Factor Interferon Gamma-Inducible Protein 16 (IFI16) Mediate Immune Signaling and Herpes Simplex Virus-1 Immunosuppression.

LARP1 IFI16 MBD2 ADD1

1.20e-0433227425693804
Pubmed

Diverse functions of myosin VI elucidated by an isoform-specific α-helix domain.

EPRS1 AP2B1

1.33e-042227226950368
Pubmed

MKRN2 Physically Interacts with GLE1 to Regulate mRNA Export and Zebrafish Retinal Development.

LARP1 EPRS1 PARD3 AP2B1

1.61e-0435827432460013
Pubmed

BioID-based intact cell interactome of the Kv1.3 potassium channel identifies a Kv1.3-STAT3-p53 cellular signaling pathway.

LARP1 EPRS1 LMAN1 PARD3 ADD1

1.92e-0470827539231216
Pubmed

Muscle developmental defects in heterogeneous nuclear Ribonucleoprotein A1 knockout mice.

USP28 MEF2C

2.49e-043027228077597
Pubmed

p62/SQSTM1 Fuels Melanoma Progression by Opposing mRNA Decay of a Selective Set of Pro-metastatic Factors.

EPRS1 PARD3 AP2B1

2.53e-0415927330581152
Pubmed

Genome-wide association and longitudinal analyses reveal genetic loci linking pubertal height growth, pubertal timing and childhood adiposity.

ILRUN DDX55

3.21e-043427223449627
Pubmed

Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in β-Catenin-Active Cancers.

LARP1 EPRS1 NCOR2 PARD3 AP2B1 ADD1

3.25e-04124727627684187
Pubmed

Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma.

LARP1 EPRS1 DDX55 AP2B1 IFI16 ADD1

3.39e-04125727636526897
Pubmed

Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.

CASS4 MEF2C

3.80e-043727224162737
Pubmed

New roles for the de-ubiquitylating enzyme OTUD4 in an RNA-protein network and RNA granules.

CPEB3 LARP1 AP2B1 WNK2

4.23e-0446227431138677
Pubmed

An organelle-specific protein landscape identifies novel diseases and molecular mechanisms.

MAML1 LARP1 LMAN1 PARD3 AP2B1 MBD2

4.42e-04132127627173435
Pubmed

High-sensitivity profiling of SARS-CoV-2 noncoding region-host protein interactome reveals the potential regulatory role of negative-sense viral RNA.

LARP1 EPRS1 DDX55 IFI16

4.48e-0446927437314180
Pubmed

Proteome analysis of the HIV-1 Gag interactome.

LARP1 EPRS1

5.38e-044427225010285
Pubmed

The trafficking protein Tmed2/p24beta(1) is required for morphogenesis of the mouse embryo and placenta.

NCOR2 DDX55

5.38e-044427220178780
Pubmed

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes.

NCOR2 MBD2

5.63e-044527221258344
Pubmed

RBR-type E3 ubiquitin ligase RNF144A targets PARP1 for ubiquitin-dependent degradation and regulates PARP inhibitor sensitivity in breast cancer cells.

EPRS1 ADD1

6.14e-044727229212245
Pubmed

Spatiotemporal transcriptomic atlas of mouse organogenesis using DNA nanoball-patterned arrays.

NRXN3 MEF2C

6.14e-044727235512705
Pubmed

GREB1: An evolutionarily conserved protein with a glycosyltransferase domain links ERα glycosylation and stability to cancer.

LARP1 EPRS1 AP2B1

6.79e-0422327333731348
Pubmed

FIP200 controls the TBK1 activation threshold at SQSTM1/p62-positive condensates.

LARP1 LMAN1 USP28

6.79e-0422327334226595
Pubmed

N-Terminal Acetyltransferase Naa40p Whereabouts Put into N-Terminal Proteoform Perspective.

LARP1 EPRS1 AP2B1 USP28 ADD1

6.82e-0493427533916271
Pubmed

TBK1 phosphorylation activates LIR-dependent degradation of the inflammation repressor TNIP1.

LARP1 EPRS1 DDX55 AP2B1 IFI16

7.33e-0494927536574265
InteractionCEBPA interactions

MAML1 LARP1 EPRS1 NCOR2 LMAN1 DDX55 AP2B1 IFI16 MBD2 ZNF174

2.50e-0612452710int:CEBPA
CytobandEnsembl 112 genes in cytogenetic band chr10q23

CPEB3 PLCE1

5.87e-03195272chr10q23
CytobandEnsembl 112 genes in cytogenetic band chr18q21

LMAN1 MBD2

6.47e-03205272chr18q21
CoexpressionGSE17721_POLYIC_VS_GARDIQUIMOD_4H_BMDC_UP

CPEB3 ILRUN EPRS1 BRDT MBD2

1.42e-06200265M4021
CoexpressionGSE41176_UNSTIM_VS_ANTI_IGM_STIM_BCELL_1H_DN

CASS4 EPRS1 IFI16 MBD2

4.23e-05199264M9913
CoexpressionHOLLMANN_APOPTOSIS_VIA_CD40_UP

ILRUN NCOR2 MBD2 MEF2C

4.57e-05203264M9695
ToppCellTCGA-Bile_Duct-Primary_Tumor-Cholangiocarcinoma-Intrahepatic|TCGA-Bile_Duct / Sample_Type by Project: Shred V9

LARP1 EPRS1 NCOR2 PARD3 AP2B1

1.23e-072002751fa8422fd820d21e285a7e7c4c6fbd8b7277d2af
ToppCellrenal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

NRXN3 MEF2C WNK2 PLCE1

4.91e-061892747fbe855bfdb47d35e040b04a80fe4b729a3764e8
ToppCellrenal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

NRXN3 MEF2C WNK2 PLCE1

4.91e-0618927406b35abecd29f902cf251fcc1f6ad33db7ab08a2
ToppCellControl-Epithelial_alveolar-Mes-Like|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

MAML1 DDX55 WNK2

4.67e-05116273df7609503782d8d7e4f31ed2a626916e5474d5bc
ToppCellkidney_cells-Adult_normal_reference-Mesenchymal--glomerular_mesenchymal_cell-Renin-positive_Juxtaglomerular_Granular_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

NRXN3 MEF2C PLCE1

1.26e-04162273c7114e24cb5525abb9780ca3d35dbcc4eabd4b64
ToppCellkidney_cells-Adult_normal_reference-Mesenchymal--glomerular_mesenchymal_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

NRXN3 MEF2C PLCE1

1.26e-04162273f1851a173d3bcca2981d934161ec85d1cc0af5a2
ToppCellkidney_cells-Adult_normal_reference-Mesenchymal-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

NRXN3 MEF2C PLCE1

1.26e-041622735d902bb31e691aea9749617cc88303c2448f24b8
ToppCellDendritic_Cells-Donor_02|World / lung cells shred on cell class, cell subclass, sample id

CASS4 IFI16 MEF2C

1.35e-04166273fbeb74b98b58085de323f744b18d4a8f7b22d5d4
ToppCelldroplet-Kidney-nan-3m-Lymphocytic-CD45____B_cell|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

ODAD4 DDX55 MEF2C

1.45e-041702736210ee3bf29059e6149c047bb7e02c5f59441519
ToppCellkidney_cells-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

MEF2C WNK2 PLCE1

1.53e-04173273901b8e6909c1f3849906fad9cee17b8f0bab050d
ToppCellkidney_cells-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

MEF2C WNK2 PLCE1

1.53e-04173273fc2602b2ce051cd4c33957d7e3d041ff8a529883
ToppCellfacs-Marrow-KLS-3m-Lymphocytic-immature_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

MAML1 BRDT WNK2

1.53e-041732738bffd512a4e561e23cc04478e2ca6fd5d3771fe4
ToppCellfacs-Marrow-KLS-3m-Lymphocytic-immature_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

MAML1 BRDT WNK2

1.53e-041732733e3c61468e703330788a10d850ef41a85680f86d
ToppCellfacs-Heart-RV-18m-Mesenchymal-smooth_muscle_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FAM81A WNK2 PLCE1

1.58e-04175273d8e385320f554d974538b7cdc4f8e4767f1455f2
ToppCellrenal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

NRXN3 WNK2 PLCE1

1.58e-04175273d52794426f2703a80e91ae0a8ff2d8e0ce4aa4a8
ToppCellrenal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

NRXN3 WNK2 PLCE1

1.58e-04175273454f03e6109d65f5db08dbb41ecc19ffb6bbc4e0
ToppCellfacs-Heart-RV-18m-Mesenchymal-smooth_muscle_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FAM81A WNK2 PLCE1

1.58e-04175273cf15465855602ba135752c18755e3e058dbd42ec
ToppCellPND10-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal-Deuterosomal|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

ODAD4 AGBL2 FAM81A

1.61e-04176273d6d7e4e937d49a5c0d16322c8dd3bf9e97eb8732
ToppCellPND10-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal-Deuterosomal-Deuterosomal_mature|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

ODAD4 AGBL2 FAM81A

1.61e-04176273c03d80df2550c0d2b0452326480d6bf21d20fdd2
ToppCellCiliated_cells-A-IPF_01|World / lung cells shred on cell class, cell subclass, sample id

ODAD4 AGBL2 WNK2

1.66e-04178273255473ee6df8a13079fb3bb61038162a40cb4c2c
ToppCellLV-07._Pericyte|World / Chamber and Cluster_Paper

PARD3 MEF2C PLCE1

1.80e-04183273273db6a3b00a93ca852498471187b642b5368185
ToppCellfacs-Heart-LA-3m-Mesenchymal-smooth_muscle_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FAM81A MEF2C PLCE1

1.80e-041832738d45dff06a199b1369576657f7f9dc0249c5f841
ToppCellfacs-Heart-LA-3m-Mesenchymal-smooth_muscle_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FAM81A MEF2C PLCE1

1.80e-04183273421265fa15d5a028cb567bb0904e670473ef102b
ToppCelldroplet-Marrow-nan-3m-Lymphocytic-late_pro-B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CPEB3 LMAN1 MEF2C

1.83e-0418427342cadfdb5d29a50bd7e901ddd14d42b39e8474f0
ToppCellAdult-Epithelial-ciliated_cell-D175|Adult / Lineage, Cell type, age group and donor

ODAD4 AGBL2 FAM81A

1.86e-0418527330f4980dee6cd5959655f8d74049f3bfb5312611
ToppCellfacs-Brain_Non-Myeloid-Striatum-24m-Mesenchymal-brain_pericyte|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

USP28 MEF2C PLCE1

1.86e-0418527338486b69c48dc5e1c4e1488208fa8954a973eccb
ToppCellCOVID-19-Epithelial_cells-Airway_club|COVID-19 / group, cell type (main and fine annotations)

NRXN3 PARD3 WNK2

1.86e-04185273cfe6fd73d817e173fe803bc1683c291d9bcb8608
ToppCellfacs-Brain_Non-Myeloid-Striatum-24m-Mesenchymal-Pericyte|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

USP28 MEF2C PLCE1

1.86e-041852733c28b5ceba3cfdb6f7e32d5b42e03b6a81a7a658
ToppCellLV-07._Pericyte|LV / Chamber and Cluster_Paper

PARD3 MEF2C PLCE1

1.86e-04185273acb38eba871ec72f2a8136a33b87d33b8c85465d
ToppCellLPS-IL1RA+antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_3|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

FAM81A MEF2C PLCE1

1.89e-04186273a95744b8649096bd7cfc3591a02841fa411085b3
ToppCelldroplet-Lung-LUNG-1m-Epithelial-Ciliated_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

AGBL2 FAM81A WNK2

1.92e-041872730334fb1247a5800bf1438a48da8fd905df000d89
ToppCellrenal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

NRXN3 MEF2C PLCE1

1.92e-04187273530e4e6d91b5c0d9aa4543caa2b734a1674c5788
ToppCelldroplet-Lung-LUNG-1m-Epithelial|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

AGBL2 FAM81A WNK2

1.92e-041872736288da8cdd450c58df00ebcfcc118f01fab7e610
ToppCelldroplet-Lung-LUNG-1m-Epithelial-ciliated_columnar_cell_of_tracheobronchial_tree|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

AGBL2 FAM81A WNK2

1.92e-04187273cf8e3448402e1d05b8321a5f124bd29e30e18841
ToppCellrenal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

NRXN3 MEF2C PLCE1

1.92e-04187273ec4b694487cc446999c7b27b119950a4f252c4b3
ToppCellrenal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

MEF2C WNK2 PLCE1

1.95e-04188273b2d68a32314e9b099ed74d974079ad96359d1ae3
ToppCellPND01-Epithelial-Epithelial_Airway|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

ODAD4 AGBL2 FAM81A

1.98e-0418927338cde34295566a4ecaf7d0a81c5a192cf17d0459
ToppCellrenal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

MEF2C WNK2 PLCE1

1.98e-041892732cfb4d12f75678d1619f4743838a0e954bd57761
ToppCellLPS_only-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_3|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

FAM81A MEF2C PLCE1

1.98e-04189273975e7aa3b862a8b07c2ab8426a14f5cc54998aca
ToppCellAdult|World / Lineage, Cell type, age group and donor

NCOR2 NRXN3 PPP4R4

1.98e-041892735cd285bfad973125d46d704fec18b21266a63379
ToppCellrenal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

MEF2C WNK2 PLCE1

1.98e-04189273127ad2ba3e794df8cce2eee3e4171bccb5aad51b
ToppCellIPF-Epithelial-Goblet|IPF / Disease state, Lineage and Cell class

NRXN3 PARD3 WNK2

2.01e-04190273e41dd5a997ad9952810ffecb57737c03ea1d88b3
ToppCellIPF-Epithelial-Goblet|World / Disease state, Lineage and Cell class

NRXN3 PARD3 WNK2

2.01e-04190273c29dabf0826663b9d6df51a7af9b76592090e44c
ToppCellfacs-Lung-3m-Epithelial-airway_epithelial-lung_ciliated_cell-ciliated_cell|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

ODAD4 AGBL2 FAM81A

2.04e-04191273649fcb62ad15de2f83e61591e43923a717664ae7
ToppCellfacs-Lung-3m-Epithelial-airway_epithelial-lung_ciliated_cell|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

ODAD4 AGBL2 FAM81A

2.04e-041912739621e22e14ea069f22713947c9faa2d882abe5fe
ToppCellPND01-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

ODAD4 AGBL2 FAM81A

2.04e-0419127396483adb97c81208aa513782550acd8a08b63866
ToppCellTCGA-Stomach-Primary_Tumor-Stomach_Adenocarcinoma-Stomach_Adenocarcinoma_-_NOS-6|TCGA-Stomach / Sample_Type by Project: Shred V9

EPRS1 AP2B1 FAM81A

2.08e-041922734e689bca7a242f8482e25f273656e2caba8821c0
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

NRXN3 WNK2 PLCE1

2.08e-04192273b54b0d5b88139905521c8d5d58332e89c08d589c
ToppCellwk_20-22-Mesenchymal-Myofibro_&_SMC-Vascular_SMC_2|wk_20-22 / Celltypes from embryonic and fetal-stage human lung

FAM81A MEF2C PLCE1

2.08e-04192273a7d08416f07f29ad920168a3b52ddf992f263bf4
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

NRXN3 WNK2 PLCE1

2.08e-04192273bfab13793e54de2550ee171397f7ece0625cdb4a
ToppCellhuman_hepatoblastoma-Tumor_cells|human_hepatoblastoma / Sample and Cell Type and Tumor Cluster (all cells)

NRXN3 PARD3 WNK2

2.11e-04193273503a979328c68b096680b71359a26f02fafdff35
ToppCellPBMC_fresh-frozen-Severe-critical_progression_d12-22-Lymphocytic-Lymphocytic_B-Plasma_cell-B_c05-MZB1-XBP1|Severe-critical_progression_d12-22 / Compartment, severity and other cell annotations on 10x 3' data (130k)

EPRS1 LMAN1 MEF2C

2.11e-0419327343ffa8ecc72bebcd204279db2bde98ae48d97f90
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

MEF2C WNK2 PLCE1

2.14e-041942735c3b2b05d1e4f146551fe4c920263d8e6ca34de3
ToppCellPBMC_fresh-frozen-Severe-critical_progression_d12-22-Lymphocytic-Lymphocytic_B-Plasma_cell|Severe-critical_progression_d12-22 / Compartment, severity and other cell annotations on 10x 3' data (130k)

EPRS1 LMAN1 MEF2C

2.14e-04194273297286c57d7ee6338d9cf77b27eb2809378ce15d
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

MEF2C WNK2 PLCE1

2.14e-04194273ab9cad697f9209d2889bc02b43b502dfeb2ebfef
ToppCellBrain_organoid-organoid_Paulsen_bioRxiv-1_mon-Proliferating-Cycling_Progenitors|1_mon / Sample Type, Dataset, Time_group, and Cell type.

MAML1 LARP1 PARD3

2.31e-04199273358c4b3037f59378db8916a2fbe9ed4830cf1449
ToppCellLPS_IL1RA_TNF-Mesenchymal_myocytic-Pericyte|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type

FAM81A MEF2C PLCE1

2.34e-04200273b5b5a32925f225610fe25a021a742d6397162863
ToppCellSigmoid-B_cell-B_cell_IgG_Plasma|Sigmoid / Region, Cell class and subclass

EPRS1 LMAN1 MEF2C

2.34e-04200273ad24dfdb87679bdad8b82ca3fe9f261ab75c4f68
ToppCellControl_saline-Mesenchymal_myocytic-Pericyte|Control_saline / Treatment groups by lineage, cell group, cell type

FAM81A MEF2C PLCE1

2.34e-04200273cb7ef774b6d300f8019c5b16a04e3ebd165e4f1c
ToppCellControl_saline-Mesenchymal_myocytic-Pericyte-Pericyte_3|Control_saline / Treatment groups by lineage, cell group, cell type

FAM81A MEF2C PLCE1

2.34e-04200273b0866b497aa71d06cef25f9a335fa584e95fa7e0
ToppCellLPS_IL1RA_TNF-Mesenchymal_myocytic-Pericyte-Pericyte_3|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type

FAM81A MEF2C PLCE1

2.34e-04200273c06426f877919bdd267ea2fd7e7973c6619832ae
ToppCellBrain_organoid-organoid_Tanaka_cellReport-5w-Neuronal-Intermediate|5w / Sample Type, Dataset, Time_group, and Cell type.

NRXN3 WNK2 FAM219A

2.34e-04200273c92e4fc0442404481fcac623d691dae6215b852d
ToppCellSigmoid-(2)_B_cell-(21)_B_cell_IgG_Plasma|Sigmoid / shred on region, Cell_type, and subtype

EPRS1 LMAN1 MEF2C

2.34e-042002732827ea5ef5bf395c67376da66a44071ddca46a52
ToppCellLPS_only-Mesenchymal_myocytic-Pericyte-Pericyte_3|LPS_only / Treatment groups by lineage, cell group, cell type

FAM81A MEF2C PLCE1

2.34e-042002737c62678cf408aaaf98d6df0fb27814d2007c4521
ToppCellNeuronal-Inhibitory-iB|Neuronal / cells hierarchy compared to all cells using T-Statistic

NRXN3 PARD3 PLCE1

2.34e-0420027345ddc5ef2caa87ada88327b63ba9b150a6bb3aa5
DrugMianserine hydrochloride [21535-47-7]; Up 200; 13.2uM; MCF7; HT_HG-U133A

CPEB3 MAML1 AGBL2 MBD2 PLCE1

2.13e-061892652231_UP
DrugNisoxetine hydrochloride [57754-86-6]; Up 200; 13uM; MCF7; HT_HG-U133A

MAML1 LMAN1 AGBL2 PARD3 MBD2

2.68e-061982656496_UP
DrugFlupentixol dihydrochloride cis-(Z) [2413-38-9]; Down 200; 7.8uM; HL60; HT_HG-U133A

EPRS1 LMAN1 PARD3 MEF2C

5.96e-051892641288_DN
DrugMidodrine hydrochloride [3092-17-9]; Down 200; 13.8uM; PC3; HT_HG-U133A

LMAN1 AP2B1 IFI16 ADD1

6.60e-051942642087_DN
DrugPHA-00846566E [724718-26-7]; Up 200; 10uM; PC3; HT_HG-U133A

LMAN1 IFI16 ZNF174 PLCE1

6.60e-051942647086_UP
DrugGBR 12909 dihydrochloride [67469-78-7]; Down 200; 7.6uM; MCF7; HT_HG-U133A

CASS4 LMAN1 ZNF174 PPP4R4

6.73e-051952645702_DN
DrugGraveoline [485-61-0]; Up 200; 14.4uM; MCF7; HT_HG-U133A

IFI16 MBD2 MEF2C PLCE1

6.73e-051952644738_UP
DrugLevonordefrin [829-74-3]; Down 200; 21.8uM; HL60; HT_HG-U133A

PARD3 ZNF174 MEF2C PPP4R4

6.86e-051962642710_DN
DrugDisopyramide [3737-09-5]; Up 200; 11.8uM; PC3; HT_HG-U133A

NRXN3 LMAN1 IFI16 ZNF174

6.86e-051962647276_UP
DrugOxprenolol hydrochloride [6452-73-9]; Up 200; 13.2uM; PC3; HT_HG-U133A

NRXN3 LMAN1 ZNF174 PPP4R4

6.86e-051962645871_UP
DrugTropine [120-29-6]; Down 200; 28.4uM; HL60; HT_HG-U133A

MAML1 PARD3 ZNF174 PPP4R4

6.86e-051962646147_DN
DrugDroperidol [548-73-2]; Up 200; 10.6uM; MCF7; HT_HG-U133A

CASS4 NCOR2 PPP4R4 PLCE1

7.00e-051972642645_UP
DrugThalidomide [50-35-1]; Down 200; 15.4uM; PC3; HT_HG-U133A

ILRUN LMAN1 IFI16 ADD1

7.00e-051972642095_DN
DrugThioperamide maleate [106243-16-7]; Down 200; 9.8uM; HL60; HT_HG-U133A

MAML1 CASS4 NCOR2 PLCE1

7.00e-051972643055_DN
DrugAzathioprine [446-86-6]; Up 200; 14.4uM; MCF7; HT_HG-U133A

CPEB3 NCOR2 PARD3 MBD2

7.00e-051972645262_UP
DrugLY 294002; Up 200; 0.1uM; HL60; HT_HG-U133A

CPEB3 MEF2C PPP4R4 PLCE1

7.00e-051972642676_UP
DrugAtropine-N-oxide hydrochloride [4574-60-1]; Up 200; 11.8uM; PC3; HT_HG-U133A

MAML1 CASS4 NCOR2 PPP4R4

7.14e-051982644476_UP
DrugProxyphylline [603-00-9]; Up 200; 16.8uM; MCF7; HT_HG-U133A

NCOR2 MBD2 MEF2C PPP4R4

7.14e-051982646494_UP
DrugTyloxapol [25301-02-4]; Up 200; 4uM; MCF7; HT_HG-U133A

NCOR2 MBD2 MEF2C PLCE1

7.14e-051982645672_UP
DrugMolsidomine [25717-80-0]; Up 200; 16.6uM; PC3; HT_HG-U133A

NCOR2 NRXN3 ZNF174 PPP4R4

7.28e-051992646325_UP
DrugDihydroergotoxine mesylate [8067-24-1]; Down 200; 6.4uM; PC3; HT_HG-U133A

NCOR2 MBD2 MEF2C PPP4R4

7.28e-051992644071_DN
DrugTocainide hydrochloride; Up 200; 17.4uM; PC3; HT_HG-U133A

MAML1 NCOR2 MBD2 PPP4R4

7.28e-051992644256_UP
Drugchlorpromazine hydrochloride; Up 200; 1uM; HL60; HT_HG-U133A

NCOR2 AGBL2 MBD2 PPP4R4

7.28e-051992642677_UP
Drugtridecane

NCOR2 MBD2 MEF2C

3.32e-04119263CID000012388
Drug1kkq

NCOR2 MEF2C

7.71e-0436262CID000446738
DrugEmetine dihydrochloride [316-42-7]; Down 200; 7.2uM; HL60; HT_HG-U133A

LARP1 EPRS1 LMAN1

8.60e-041652632145_DN
DrugDB08184

NCOR2 BRDT MBD2

8.90e-04167263CID009547945
Drugbelinostat

LMAN1 IFI16 USP28 PPP4R4 PLCE1

9.03e-04678265ctd:C487081
DrugCephaeline dihydrochloride heptahydrate [6487-30-5]; Down 200; 6uM; HL60; HT_HG-U133A

LARP1 EPRS1 AP2B1

9.53e-041712632429_DN
DrugDequalinium dichloride [522-51-0]; Down 200; 7.6uM; HL60; HT_HG-U133A

LMAN1 PARD3 IFI16

1.00e-031742631276_DN
DrugAlexidine dihydrochloride [22573-93-9]; Up 200; 6.8uM; MCF7; HT_HG-U133A

NCOR2 NRXN3 MEF2C

1.09e-031792634721_UP
Drugmercuric bromide

NRXN3 LMAN1 IFI16 MBD2 USP28 PLCE1

1.12e-031076266ctd:C042720
DrugChelidonine monohydrate (+) [476-32-4]; Down 200; 10.8uM; HL60; HG-U133A

LARP1 EPRS1 IFI16

1.12e-031812631786_DN
Drug17-AAG; Up 200; 1uM; MCF7; HT_HG-U133A

CPEB3 LMAN1 PPP4R4

1.12e-031812635578_UP
Drugpioglitazone HCl; Down 200; 10uM; PC3; HT_HG-U133A

ILRUN LMAN1 AP2B1

1.16e-031832637088_DN
DrugCorticosterone [50-22-6]; Up 200; 11.6uM; MCF7; HT_HG-U133A

LMAN1 AGBL2 PPP4R4

1.18e-031842633244_UP
Drug2-propylpentanoic acid; Up 200; 1000uM; HL60; HT_HG-U133A

IFI16 ZNF174 MEF2C

1.18e-031842632669_UP
DrugPrenylamine lactate [69-43-2]; Up 200; 9.6uM; HL60; HG-U133A

LMAN1 PARD3 IFI16

1.18e-031842631737_UP
Drug17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A_EA

PARD3 ZNF174 ADD1

1.21e-03186263831_DN
DrugThonzonium bromide [553-08-2]; Up 200; 6.8uM; MCF7; HT_HG-U133A

NCOR2 PARD3 MEF2C

1.23e-031872635678_UP
DrugThiostrepton [1393-48-2]; Up 200; 2.4uM; MCF7; HT_HG-U133A

NCOR2 MBD2 PLCE1

1.25e-031882634385_UP
Druggenistein; Down 200; 10uM; HL60; HT_HG-U133A

LARP1 NCOR2 ZNF174

1.25e-031882631176_DN
DrugEthotoin [86-35-1]; Down 200; 19.6uM; PC3; HT_HG-U133A

ILRUN EPRS1 LMAN1

1.25e-031882634545_DN
DrugNeostigmine bromide [114-80-7]; Down 200; 13.2uM; PC3; HT_HG-U133A

EPRS1 LMAN1 IFI16

1.25e-031882636735_DN
DrugDicyclomine hydrochloride [67-92-5]; Up 200; 11.6uM; MCF7; HT_HG-U133A

CPEB3 LMAN1 PPP4R4

1.25e-031882634405_UP
DrugCloperastine hydrochloride [14984-68-0]; Down 200; 11uM; PC3; HT_HG-U133A

ILRUN EPRS1 IFI16

1.27e-031892634271_DN
Drugtroglitazone; Down 200; 10uM; HL60; HT_HG-U133A

CASS4 NCOR2 PLCE1

1.27e-031892632692_DN
DrugEconazole nitrate [24169-02-6]; Down 200; 9uM; PC3; HT_HG-U133A

NCOR2 NRXN3 LMAN1

1.29e-031902637305_DN
DrugLuteolin [491-70-3]; Down 200; 14uM; HL60; HT_HG-U133A

PARD3 IFI16 ZNF174

1.29e-031902633041_DN
DrugMyricetin [529-44-2]; Down 200; 12.6uM; HL60; HT_HG-U133A

MAML1 PARD3 ZNF174

1.29e-031902631334_DN
DrugKN 62

NCOR2 MEF2C

1.31e-0347262ctd:C063302
DrugMeclofenoxate hydrochloride [3685-84-5]; Down 200; 13.6uM; PC3; HT_HG-U133A

ILRUN EPRS1 LMAN1

1.33e-031922634268_DN
Drug2-propylpentanoic acid; Down 200; 1000uM; MCF7; HT_HG-U133A

MAML1 LMAN1 AP2B1

1.33e-031922635206_DN
Drug15(S)-15-methyl Prostaglandin E2; Up 200; 10uM; PC3; HT_HG-U133A

NCOR2 LMAN1 ZNF174

1.33e-031922637526_UP
DrugAG-013608 [351320-38-2]; Down 200; 10uM; MCF7; HT_HG-U133A

ILRUN EPRS1 ADD1

1.33e-031922636435_DN
DrugC75; Down 200; 10uM; MCF7; HT_HG-U133A

AP2B1 ZNF174 PPP4R4

1.33e-031922636423_DN
DrugEthisterone [434-03-7]; Up 200; 12.8uM; PC3; HT_HG-U133A

CPEB3 MBD2 PPP4R4

1.33e-031922634340_UP
DrugY-27632; Up 200; 3uM; MCF7; HT_HG-U133A_EA

NCOR2 LMAN1 AP2B1

1.35e-03193263948_UP
DrugPramoxine hydrochloride [637-58-1]; Up 200; 12.2uM; PC3; HT_HG-U133A

NCOR2 NRXN3 LMAN1

1.35e-031932633811_UP
DrugLovastatin [75330-75-5]; Up 200; 9.8uM; MCF7; HT_HG-U133A

LMAN1 ADD1 PLCE1

1.35e-031932634978_UP
DrugSelegiline hydrochloride [14611-52-0]; Up 200; 17.8uM; MCF7; HT_HG-U133A

NCOR2 MBD2 MEF2C

1.35e-031932634146_UP
DrugIsocarboxazid [59-63-2]; Up 200; 17.2uM; PC3; HT_HG-U133A

NRXN3 AP2B1 PPP4R4

1.35e-031932633684_UP
DrugMephentermine hemisulfate [1212-72-2]; Down 200; 9.4uM; HL60; HT_HG-U133A

LMAN1 ZNF174 MEF2C

1.35e-031932632563_DN
DrugParbendazole [14255-87-9]; Down 200; 16.2uM; PC3; HT_HG-U133A

LMAN1 ZNF174 PPP4R4

1.35e-031932633799_DN
DrugMetanephrine hydrochloride DL [881-95-8]; Down 200; 17.2uM; PC3; HT_HG-U133A

CASS4 NRXN3 MEF2C

1.35e-031932636734_DN
DrugTiratricol, 3,3',5-triiodothyroacetic acid [51-24-1]; Down 200; 6.4uM; HL60; HG-U133A

ILRUN AP2B1 IFI16

1.35e-031932631412_DN
DrugBretylium tosylate [61-75-6]; Up 200; 9.6uM; MCF7; HT_HG-U133A

LMAN1 AP2B1 MBD2

1.35e-031932635020_UP
DrugLithocholic acid [434-13-9]; Up 200; 10.6uM; MCF7; HT_HG-U133A

NCOR2 AP2B1 PLCE1

1.37e-031942634373_UP
DrugBacampicillin hydrochloride [37661-08-8]; Down 200; 8uM; MCF7; HT_HG-U133A

MAML1 LMAN1 PPP4R4

1.37e-031942634417_DN
DrugICI 182,780; Up 200; 0.01uM; MCF7; HT_HG-U133A

AP2B1 MBD2 MEF2C

1.37e-031942635235_UP
DrugBAS 012416453; Down 200; 38uM; PC3; HT_HG-U133A

IFI16 ZNF174 ADD1

1.37e-031942636876_DN
DrugLomefloxacin hydrochloride [98079-52-8]; Down 200; 10.4uM; PC3; HT_HG-U133A

ILRUN LMAN1 ADD1

1.37e-031942634281_DN
DrugClobetasol propionate [25122-46-7]; Up 200; 8.6uM; MCF7; HT_HG-U133A

MAML1 AP2B1 MBD2

1.37e-031942636835_UP
Drug15d-PGJ2; Down 200; 10uM; PC3; HT_HG-U133A

NRXN3 MEF2C PPP4R4

1.37e-031942634455_DN
DrugTrichostatin A, Streptomyces sp.; Down 200; 0.1uM; HL60; HT_HG-U133A

ZNF174 MEF2C PPP4R4

1.37e-031942636171_DN
DrugBenfotiamine [22457-89-2]; Down 200; 8.6uM; PC3; HT_HG-U133A

ILRUN EPRS1 IFI16

1.37e-031942634312_DN
DrugOmeprazole [73590-58-6]; Down 200; 11.6uM; HL60; HT_HG-U133A

LMAN1 ZNF174 MEF2C

1.37e-031942632467_DN
Drugradicicol; Down 200; 0.1uM; PC3; HT_HG-U133A

NCOR2 MEF2C PPP4R4

1.37e-031942635952_DN
DrugBenzethonium chloride [121-54-0]; Down 200; 9uM; MCF7; HT_HG-U133A

MAML1 LMAN1 ZNF174

1.37e-031942636070_DN
Diseasealcohol consumption measurement

NCOR2 NRXN3 AGBL2 DDX55 PARD3 BRDT MBD2 USP28

1.05e-051242278EFO_0007878
Diseasemigraine disorder, diastolic blood pressure

NCOR2 PLCE1

2.39e-0425272EFO_0006336, MONDO_0005277
Diseasegait measurement

ILRUN NRXN3 AGBL2

3.44e-04150273EFO_0007680
Diseasedevelopmental disorder of mental health (implicated_via_orthology)

NCOR2 PARD3

9.23e-0449272DOID:0060037 (implicated_via_orthology)
Diseasebody surface area

ILRUN NCOR2 NRXN3 PARD3

2.63e-03643274EFO_0022196
DiseaseAutism Spectrum Disorders

NRXN3 MEF2C

2.75e-0385272C1510586
DiseaseDNA methylation

ILRUN PARD3 WNK2 PLCE1

2.83e-03656274GO_0006306
Diseasecortical thickness

AGBL2 PARD3 MEF2C WNK2 PLCE1

3.06e-031113275EFO_0004840
DiseaseS-warfarin measurement

NCOR2 BRDT

3.56e-0397272EFO_0803323
Diseasecorpus callosum volume measurement

WNK2 ADD1

3.78e-03100272EFO_0010299
Diseasemonocyte percentage of leukocytes

CPEB3 MAML1 MEF2C ADD1

4.17e-03731274EFO_0007989
Diseaseimmature platelet count

AP2B1 MEF2C

4.23e-03106272EFO_0803544
Diseaseplatelet component distribution width

NCOR2 AGBL2 AP2B1 MEF2C

4.67e-03755274EFO_0007984
Diseaseimmature platelet measurement

AP2B1 MEF2C

5.30e-03119272EFO_0803541
Diseasesmoking behavior, body mass index

ILRUN NRXN3

5.65e-03123272EFO_0004318, EFO_0004340
Diseaset-tau measurement

NRXN3 PARD3

5.92e-03126272EFO_0004760
Diseasecigarettes per day measurement

CPEB3 MBD2 ADD1

7.29e-03438273EFO_0006525
Diseasefacial height measurement

LARP1 MEF2C

7.46e-03142272EFO_0007856

Protein segments in the cluster

PeptideGeneStartEntry
KMEPLNNLQVAVKNN

AP2B1

796

P63010
TPQLNNNVPMQKKLS

CASS4

291

Q9NQ75
KENMPKNVLPDSQQQ

BRDT

246

Q58F21
RDQLQKQIQLMQKPE

FAM81A

351

Q8TBF8
QIAAKQKREQMLQNP

MAML1

401

Q92585
QQQQQPMPRSSQEEK

NCOR2

506

Q9Y618
PQQLPSQQLMSKDQD

LARP1

586

Q6PKG0
NQKCPLQEMKPQRNT

DDX55

386

Q8NHQ9
GSPVNQQPKKNNVMA

FAM219A

71

Q8IW50
LKVLNMAAENNPNIK

NRXN3

1241

Q9Y4C0
DNLVQRNMPSNEKPK

LMAN1

451

P49257
NLNKNMQAKSPPPMN

MEF2C

231

Q06413
KVKSDPQRMNEQPRQ

MBD2

266

Q9UBB5
PQKNRQSDENNLKDP

ILRUN

216

Q9H6K1
LMDKSKTQPQPQQQQ

CPEB3

6

Q8NE35
PMKNENPRLNETNLN

AGBL2

806

Q5U5Z8
NNDPKSMKLPQEQRQ

IFI16

396

Q16666
QRRKEQQMKKQPPSE

PARD3

1291

Q8TEW0
NKPQKQNDGQRKDPS

EPRS1

976

P07814
QLEKEKQQNDGRPMS

PPP4R4

711

Q6NUP7
KNAEKPNMQRNNTLG

PLCE1

1066

Q9P212
LKVLNMAAENNPNIK

NRXN3

236

Q9HDB5
QAENIKAQQKPQPMK

ODAD4

151

Q96NG3
PLNTNPKEVQEMRNK

ADD1

491

P35611
PRMRSDNKENPQQEG

ZNF174

211

Q15697
NKKNDEMQEAPNRVL

SPANXN2

21

Q5MJ10
NVNSPRNKSENPMVQ

USP28

276

Q96RU2
PTLNQLKQTQKLQDM

WNK2

2181

Q9Y3S1